Clinical trials: Ruxolitinib
Transplant-Related Disorder
daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCT
This study aims to evaluate the efficacy of prophylactic ruxolitinib in adult patients at intermediate-to-high risk of severe acute GvHD, as predicted by the daGOAT model.
- Trial name
- NCT07588945
- Testing
- Ruxolitinib
- Volunteers
- 438 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
AML, Adult
MRD-positive AML Clinical Study
This clinical trial is a platform-type clinical study intended to investigate the efficacy and safety of MRD-positive acute myeloid leukemia patients after comprehensive treatment, which includes but is not limited to the…
- Trial name
- NCT07131059
- Testing
- Ivosidenib, Gilteritinib, Venetoclax
- Where
- China
- Volunteers
- 537 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Severe Checkpoint Inhibitor Pneumonitis
The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor Pneumonia
This study is a prospective multicenter randomized controlled Interventional study, to assess the clinical efficacy and safety of corticosteroids compared to corticosteroids in combination with Ruxolitinib in the treatment of…
- Trial name
- NCT05899725
- Testing
- Corticosteroids, Corticosteroids and Ruxolitinib
- Where
- 4 sites in China
- Volunteers
- 60 people
- Sponsor
- Peking Union Medical College Hospital
Acute Leukemia, Myelodysplastic Syndromes
Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNI
Graft-versus-host disease (GVHD) is an important complication after transplantation, with an incidence of 40-60%, which can increase non-relapse mortality if poorly controlled.
- Conditions
- Acute Leukemia, Myelodysplastic Syndromes, Severe Aplastic Anemia (SAA)
- Trial name
- NCT07796620
- Testing
- Sirolimus, Ruxolitinib, MMF
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Graft Versus Host Disease, JNS Kinase
Topical Ruxolitinib for Cutaneous Chronic Graft Versus Host Disease (cGVHD)
Background: About half the people who have a hematopoietic stem cell transplant using donor cells get Chronic Graft Versus Host Disease (cGVHD). This is chronic graft versus host disease.
- Conditions
- Graft Versus Host Disease, JNS Kinase, Topical Administration
- Trial name
- NCT03395340
- Testing
- Ruxolitinib 1.5% cream, vehicle cream
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Macrophage Activation Syndrome
Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation Syndrome
The present study was a single-center, prospective, non-comparative in which macrophage activation syndrome patients were selected as the main subjects to evaluate the effect and safety of Ruxolitinib and methylprednisolone…
- Trial name
- NCT05137496
- Testing
- Ruxolitinib, methylprednisolone
- Volunteers
- 40 people
- Sponsor
- Beijing Friendship Hospital
Hemophagocytic Lymphohistiocytosis (HLH)
Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis
This study is trying to evaluate the efficacy and safety of dose-modified Emapalumab and Ruxolitinib (E-Ru) regimens for the treatment of active hemophagocytic lymphohistiocytosis.
- Trial name
- NCT06951971
- Testing
- dose-modified E-Ru, Salvage treatment and follow-up
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Non Small Cell Lung Carcinoma, Renal Cell Carcinoma
Retifanlimab and Ruxolitinib In Solid Malignancies
The goal of this clinical trial is to learn what dose of ruxolitinib can be given safely together with retifanlimab in patients with metastatic renal cell carcinoma and non-small cell lung carcinoma.
- Trial name
- PRISM (NCT07219576)
- Testing
- Ruxolitinib, Retifanlimab
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of California, San Diego
Leukemia
Phase l/II Study of Ruxolitinib for Acute Leukemia
The goal of this clinical research study is to find the highest tolerable dose of ruxolitinib that can be given to patients with acute leukemia and to learn if the study drug can help control the disease.
- Trial name
- NCT01251965
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- M.D. Anderson Cancer Center
Hidradenitis Suppurativa
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in participants with hidradenitis suppurativa.
- Trial name
- NCT06958211
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 107 sites in United States, Belgium and 7 more
- Volunteers
- 573 people
- Sponsor
- Incyte Corporation
Graft Versus Host Disease
Ruxolitinib With Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor Plus Methotrexate and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis for HLA-haploidentical Hematopoietic Stem Cell Transplantation
Low Dose Ruxolitinib with Calcineurin Inhibitor and Methotrexate vs. Calcineurin Inhibitor plus Methotrexate and Mycophenolate mofetil as Graft Versus Host Disease prophylaxis for HLA-haploidentical hematopoietic stem cell…
- Trial name
- NCT04838704
- Testing
- Ruxolitinib+Calcineurin inhibitor+Methotrexate, Calcineurin Inhibitor+Methotrexate+Mycophenolate mofetil
- Where
- China
- Volunteers
- 215 people
- Sponsor
- Zhejiang University
Acute-graft-versus-host Disease
Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids
This multi-center center phase I/II study to establish the lowest possible recommended phase 2 dose (RP2D) of corticosteroids in conjunction with ruxolitinib and uhCG/EGF (a novel combination) for high-risk aGVHD.
- Trial name
- NCT05123040
- Testing
- Ruxolitinib 10 MG Oral Tablet, hCG, Corticosteroids
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Non-Segmental Vitiligo (NSV)
Ruxolitinib Cream Combined With Corticosteroids for Progressive Non-Segmental Vitiligo: A Multicenter Real-World Study
This study is a prospective, multicenter, real-world observational study to assess the clinical efficacy and safety of topical 1.5% Ruxolitinib phosphate cream used in combination with systemic corticosteroids in a real-world…
- Trial name
- NCT07673640
- Testing
- 1.5% Ruxolitinib Phosphate Cream (Opzelura), Corticosteroid Therapy
- Where
- 20 sites in China
- Volunteers
- 300 people
- Sponsor
- ShanShan Li
Graft-Versus-Host Disease
A Study of Ruxolitinib in Patients With Graft-Versus Host Disease
This study aims to evaluate the safety and effectiveness of Jakavi® (ruxolitinib) in patients with acute graft-versus host disease (GVHD) and chronic GVHD in clinical practice.
- Trial name
- NCT07594587
- Where
- Japan
- Volunteers
- 395 people
- Sponsor
- Novartis Pharmaceuticals
NonSegmental Vitiligo
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in children (6 to < 12 years old) with nonsegmental vitiligo.
- Trial name
- NCT06804811
- Testing
- Ruxolitinib Cream, Vehicle Cream
- Where
- 78 sites in Argentina, Austria and 12 more
- Volunteers
- 250 people
- Sponsor
- Incyte Corporation
Acute Graft-versus-host Disease
Steroids Combined With Ruxolitinib as First-Line Therapy for Grade II Acute Graft-versus-Host Disease
This study aims to evaluate the efficacy and safety of low-dose corticosteroids combined with ruxolitinib in the treatment of grade II acute graft-versus-host disease (aGVHD) after allogeneic hematopoietic stem cell…
- Trial name
- NCT07576010
- Testing
- RUX+Steroids
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Daihong Liu
Graft vs Host Disease
Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant
This open-label, single-arm, Phase II multi-center study enrolled 46 participants and investigated the activity, pharmacokinetics and safety of ruxolitinib added to the subject's immunosuppressive regimen among infants, children…
- Trial name
- REACH 5 (NCT03774082)
- Testing
- INC424
- Where
- 21 sites in Brazil, Canada and 12 more
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Acute Graft Versus Host Disease
Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
The study was an open-label, single-arm, Phase I/II multi-center study to investigate the PK, activity and safety of ruxolitinib added to the patient's immunosuppressive regimen in infants, children, and adolescents ages ≥28 days…
- Trial name
- NCT03491215
- Testing
- Ruxolitinib
- Where
- 19 sites in Belgium, Canada and 6 more
- Volunteers
- 45 people
- Sponsor
- Novartis Pharmaceuticals
Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL
Current therapeutic strategies for high-risk or relapsed ALL patients often involve intensive treatments, including allogeneic hematopoietic stem cell transplantation (HSCT).
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Stem Cell Transplant, Graft -Versus-host-disease
- Trial name
- FORUM2 (NCT07297914)
- Testing
- Total Body Irradiation 8 Gy, Ruxolitinib, Blinatumomab
- Where
- 9 sites in Austria, Czechia and 7 more
- Volunteers
- 1,000 people
- Sponsor
- Bambino Gesù Hospital and Research Institute
Hemophagocytic Lymphohistiocytoses
Modified DEP Regimens for the Treatment of Hemophagocytic Lymphohistiocytosis
This study is trying to evaluate the efficacy and safety of modified DEP regimens for the treatment of active hemophagocytic lymphohistiocytosis.
- Trial name
- NCT06504030
- Testing
- modified-DEP
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University